• Atea Pharmaceuticals flagged new clinical and preclinical data across its viral hepatitis pipeline slated for presentation at EASL Congress 2026 in Barcelona on May 27-30.
• Two poster presentations will cover studies supporting its fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C, including findings that suggest common acid-reducing therapy did not meaningfully change drug exposure and that the regimen shows limited potential for key drug-transport interactions.
• A top poster will present preclinical results for AT-587, a hepatitis E candidate positioned for first-in-class potential in a disease area with no approved therapies.
• The update comes ahead of expected topline Phase 3 readouts from C-BEYOND and C-FORWARD, which remain central to the hepatitis C program’s commercial outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.